The Stockholm CREAtinine Measurements Project

Karolinska Institutet3,200,000 enrolled

Overview

The Stockholm CREAtinine Measurements (SCREAM) project is a healthcare utilization cohort including, at present, all adult residents in Stockholm between 2006 and 2021. The region of Stockholm had a population of 2.3 million citizens in 2021and provides universal healthcare with a single unified health-system. Administrative databases with complete information on socidemographic data, healthcare use, diagnoses and therapeutic/surgical procedures, and vital status were enriched with performed laboratory tests, dispensed prescriptions at Swedish pharmacies and validated kidney replacement therapy endpoints. Registries were linked and de-identified by the Swedish National Board of Welfare and are considered to have no or minimal loss to follow-up. Because the study utilized de-identified data, it was deemed not to require informed consent and was approved by the regional ethical review boards and the Swedish National Board of Welfare. For detailed description of available data and linked registers please consult: https://pubmed.ncbi.nlm.nih.gov/35028991/

Please consult cohort description in: https://pubmed.ncbi.nlm.nih.gov/35028991/ https://pubmed.ncbi.nlm.nih.gov/26798472/

Study Type

OBSERVATIONAL

Enrollment

3,200,000

Conditions

Chronic Kidney Diseases Acute Kidney Injury Diabetes Mellitus Cardiovascular Diseases

Interventions

Initiation of specific medicationsDRUG

multiple therapies studied within this database

Undertaking of specific proceduresPROCEDURE

multiple procedures/surgeries studied within this database

Abnormalities in specific laboratory testsDIAGNOSTIC_TEST

multiple abnormalities in laboratory values (i.e. CRP, cholesterol, eGFR, potassium) studied within this database

Eligibility

Sex: ALLMin age: 0 YearsMax age: 110 Years

Medical Language ↔ Plain English

Inclusion Criteria: For both cohorts: Be a resident of Stockholm during 2006-2021, of all ages For the primary cohort: To have undertaken at least one test of serum creatinine or albuminuria during 2006-2021. If this condition is met, we will then extract a broad range of laboratory tests For the secondary cohort: Anyone not undertaking a test of serum creatinine or albuminuria will conform the secondary cohort. In this cohort we will not extract any other laboratory test, but will obtain the rest of healthcare information Exclusion criteria: None

Outcomes

Primary Outcomes

Adverse health events by levels of kidney function

multiple outcomes evaluated such as cardiovascular events, fractures, dementia, cancer, etc, all of them based on claims data and/or laboratory data

Time frame: 2006-2021

Safety and efficacy of medications by levels of kidney function

multiple outcomes evaluated depending on the treatments of interest, all of them based on claims data and/or laboratory data

Time frame: 2006-2021

Effect of medications or conditions on kidney function decline

Evaluation of changes in kidney function over time upon occurrence of a certain condition (i.e., heart failure or covid19 infection) or initiation of a specific medication

Time frame: 2006-2021

Secondary Outcomes

Adverse health events associated to laboratory abnormalities

Same as primary objectives but for other laboratory abnormalities different from kidney function measures

Time frame: 2006-2021